Navigation Links
Accuray Reports Continued Growth in Second Quarter of Fiscal 2008

Fourth Consecutive Quarter of Record Revenue and Backlog

SUNNYVALE, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced financial results for the second quarter of fiscal 2008, ended December 29, 2007.

For the second quarter of fiscal 2008, Accuray reported total revenue of $52.0 million, a 98 percent increase over second quarter fiscal 2007 total revenue of $26.3 million.

Net income for the quarter ended December 29, 2007 was $2.3 million, or $0.04 per diluted share, compared to a loss of $7.3 million, or a loss of $0.45 per share, during the same period last year. Shares used in computing fully diluted earnings per share were 61.3 million for the second fiscal quarter of 2008.

Non-cash, stock-based compensation charges for the second fiscal quarter of 2008 were $4.3 million or $0.07 per diluted share.

For the period ended December 29, 2007, backlog increased to approximately $660 million, with approximately $365 million associated with CyberKnife(R) Robotic Radiosurgery System contracts and approximately $295 million associated with services and other recurring revenue. Accuray's backlog is composed of firm, signed contracts that the company believes have a substantially high probability of being recognized as revenue.

Accuray's cash balance at the end of the quarter was $187.5 million.

For the six months ended December 29, 2007, total revenue was $100.7 million, a 70 percent improvement over the $59.1 million in total revenue during the same period last year. Net income for the first half of fiscal 2008 was $4.6 million, or $0.08 per diluted share, compared to a loss of $5.3 million, or a loss of $0.33 per share, for the first half of fiscal 2007.

"Accuray continues to experience record-setting growth, with our fourth consecutive quarter of increasing revenue and backlog. This sustained growth is a testament to the impact that the CyberKnife System is having on meeting the demands for extracranial radiosurgery, particularly prostate and lung cancer," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "While this was a positive quarter with respect to revenue and backlog growth, we believe that broader credit market issues are having a short-term impact on some of our U.S. customers' purchase and installation timelines, as obtaining financing has become more difficult. We remain confident in the clinical demand for the CyberKnife and our ability to further build the market for extracranial radiosurgery."


The following statements are forward-looking and actual results may differ materially. Based upon current economic conditions, specifically the tightening of credit markets in the United States, Accuray is adjusting revenue guidance for fiscal 2008 to be in the range of $210 million to $230 million, which would represent revenue growth of 50 percent to 64 percent over fiscal 2007.

Earnings Call Open to Investors

Accuray will hold a conference call for financial analysts and investors today, January 30, 2008 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial-in numbers are (866) 288-0541 (USA) or (913) 312-1268 (International), Access Code: 4129411. A live webcast of the call will also be available from the Investor Relations section on the corporate Web site at In addition, a recording of the call will be available by calling (888) 203-1112 (USA) or (719) 457-0820 (International), Access Code: 4129411, beginning at 5:00 p.m. PT / 8:00 p.m. ET, January 30, 2008 and will be available through February 14, 2008. A webcast replay will also be available from the Investor Relations section of the corporate Web site at from approximately 5:00 p.m. PT / 8:00 p.m. ET, today, through Accuray's release of fiscal third quarter 2008 results, ending on March 29, 2008.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to financial guidance including realization of backlog, procedure growth, market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; variability of installation and sales cycle including customer financing and construction delays; competing products; the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Accuray Incorporated

Unaudited Condensed Consolidated Statements of


(in thousands, except per share data)

Three months ended Six months ended

December December December December

29, 2007 30, 2006 29, 2007 30, 2006

Net revenue:

Products $39,131 $19,309 $76,115 $46,076

Shared ownership programs 3,044 2,585 5,356 4,811

Services 8,950 3,661 15,949 6,630

Other 913 792 3,264 1,601

Total net revenue 52,038 26,347 100,684 59,118

Cost of revenue:

Costs of products 16,481 7,363 32,921 18,080

Costs of shared ownership programs 760 696 1,472 1,302

Costs of services 6,391 2,960 10,849 4,629

Costs of other 544 626 1,669 1,102

Total cost of revenue 24,176 11,645 46,911 25,113

Gross profit 27,862 14,702 53,773 34,005

Operating expenses:

Selling and marketing 11,167 9,764 21,323 17,294

Research and development 8,128 6,132 15,843 12,314

General and administrative 7,976 6,136 15,877 10,755

Total operating expenses 27,271 22,032 53,043 40,363

Income (loss) from operations 591 (7,330) 730 (6,358)

Interest and other income, net 2,197 103 4,809 310

Income (loss) before provision for

income taxes and cumulative effect of

change in accounting principle 2,788 (7,227) 5,539 (6,048)

Provision for income taxes 445 64 931 123

Income (loss) before cumulative effect

of change in accounting principle 2,343 (7,291) 4,608 (6,171)

Cumulative effect of change in

accounting principle, net - - - 838

of tax of $0

Net income (loss) $2,343 $(7,291) $4,608 $(5,333)

Net income (loss) per common share,

basic and diluted:


Income (loss) before cumulative effect

of change in

accounting principle $0.04 $(0.45) $0.08 $(0.38)

Cumulative effect of change in

accounting principle - - - 0.05

Basic net income (loss) per share $0.04 $(0.45) $0.08 $(0.33)


Income (loss) before cumulative

effect of change in

accounting principle $0.04 $(0.45) $0.08 $(0.38)

Cumulative effect of change in

accounting principle - - - 0.05

Diluted net income (loss)

per share $0.04 $(0.45) $0.08 $(0.33)

Weighted average common shares

outstanding used in computing net

income (loss) per share:

Basic 54,737 16,209 54,380 16,234

Diluted 61,293 16,209 61,257 16,234

Cost of revenue, selling and

marketing, research and development,

and general and administrative

expenses include stock-based

compensation charges as follows:

Cost of revenue $530 $232 $851 $450

Selling and marketing $1,039 $1,007 $2,146 $1,656

Research and development $803 $471 $1,478 $920

General and administrative $1,911 $1,164 $4,112 $2,062

Accuray Incorporated

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

December 29, June 30,

2007 2007


Current assets:

Cash and cash equivalents $187,482 $204,830

Accounts receivable 15,158 10,105

Inventories 15,432 16,984

Prepaid expenses and other current

assets 6,798 7,937

Deferred cost of revenue-current 28,767 30,709

Total current assets 253,637 270,565

Property and equipment, net 28,117 23,937

Goodwill 4,495 4,495

Intangible assets, net 1,055 1,184

Deferred cost of revenue-noncurrent 21,939 30,522

Other assets 1,249 1,406

Total assets $310,492 $332,109

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $9,050 $14,147

Accrued expenses 13,182 17,240

Customer advances-current 20,712 12,634

Deferred revenue-current 77,003 78,022

Total current liabilities 119,947 122,043

Long-term liabilities:

Customer advances-noncurrent 2,850 8,388

Deferred revenue-noncurrent 47,332 76,235

Total liabilities 170,129 206,666

Stockholders' equity

Preferred stock, $0.001 par value;

authorized: 5,000,000 shares at

December 29, 2007 and June 30,

2007; no shares issued and

outstanding. - -

Common stock, $0.001 par value;

authorized: 100,000,000 shares at

December 29, 2007 and June 30, 2007;

issued and outstanding: 55,267,398 and

55,045,347 shares, respectively, at

December 29, 2007 and 53,798,643 and

53,798,643 shares, respectively, at

June 30, 2007. 55 53

Additional paid-in capital 262,240 251,637

Accumulated other comprehensive

income (loss) (31) 10

Accumulated deficit (121,901) (126,257)

Total stockholders' equity 140,363 125,443

Total liabilities and stockholders'

equity $310,492 $332,109

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Accuray Incorporated to Report Second Quarter Fiscal Year 2008 Financial Results
2. Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System
3. Accuray Reports Record Revenue in First Quarter of Fiscal 2008
4. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
5. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
6. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
7. Accuray to Webcast Senior Management Presentations at Analyst Day Event
8. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
9. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
10. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
11. Encision Reports Third Fiscal Quarter Results
Post Your Comments:
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. ... the other from Bradley Beach, New Jersey, there is an easy solution to the ... replace NuvaRings more often than necessary. As such, it affords peace of mind and ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
Breaking Medicine Technology: